CRISPR rises after UK authorizes gene therapy for blood disorders

Crispr Therapeutics AG

16/11/2023 11:27

** U.S.-listed shares of Swiss gene editing co CRISPR
Therapeutics AG  CRSP.O   CRSP.BN  rise 5.28% to $59.20
premarket
    ** Co and partner Vertex Pharmaceuticals  VRTX.O  say UK's
Medicines and Healthcare products Regulatory Agency (MHRA) has
granted conditional marketing authorization for the gene therapy
to treat blood disorders 
    ** The therapy, Casgevy, based on the Nobel Prize-winning
CRISPR/Cas9 technology, aims to treat sickle cell disease (SCD)
and transfusion-dependent beta thalassemia (TDT)
     ** This marks the first regulatory authorization of a
CRISPR-based therapy in the world
    ** The therapy is also under review by the U.S. FDA, with a
set action date of Dec. 8 this year for SCD and March 30, 2024,
for TDT
    ** The MHRA said no significant safety concerns were
identified during the trials, adding it was closely monitoring
the medicine's safety 
    ** Up to last close, stock up ~39% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))